You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Impact of SARS-CoV-2 vaccination and booster on COVID-19 symptom severity over time in the COVID-OUT trial
|
|---|---|
| Published in |
Clinical Infectious Diseases, September 2022
|
| DOI | 10.1093/cid/ciac772 |
| Pubmed ID | |
| Authors |
David R Boulware, Thomas A Murray, Jennifer L Proper, Christopher J Tignanelli, John B Buse, David M Liebovitz, Jacinda M Nicklas, Kenneth Cohen, Michael A Puskarich, Hrishikesh K Belani, Lianne K Siegel, Nichole R Klatt, David J Odde, Amy B Karger, Nicholas E Ingraham, Katrina M Hartman, Via Rao, Aubrey A Hagen, Barkha Patel, Sarah L Fenno, Nandini Avula, Neha V Reddy, Spencer M Erickson, Sarah Lindberg, Regina Fricton, Samuel Lee, Adnin Zaman, Hanna G Saveraid, Walker J Tordsen, Matthew F Pullen, Nancy E Sherwood, Jared D Huling, Carolyn T Bramante, for the COVID-OUT study team |
| Abstract |
SARS-CoV-2 vaccination has decreasing protection from acquiring any infection with emergence of new variants; however, vaccination continues to protect against progression to severe COVID-19. The impact of vaccination status on symptoms over time is less clear. Within a randomized trial on early outpatient COVID-19 therapy testing metformin, ivermectin, and/or fluvoxamine, participants recorded symptoms daily for 14 days. Participants were given a paper symptom diary allowing them to circle the severity of 14 symptoms as none (0), mild (1), moderate (2), or severe (3). This is a secondary analysis of clinical trial data on symptom severity over time using generalized estimating equations comparing those unvaccinated, SARS-CoV-2 vaccinated with primary vaccine series only, or vaccine-boosted. The parent clinical trial prospectively enrolled 1323 participants, of whom 1062 (80%) prospectively recorded some daily symptom data. Of these, 480 (45%) were unvaccinated, 530 (50%) were vaccinated with primary series only, and 52 (5%) vaccine-boosted. Overall symptom severity was least for the vaccine-boosted group and most severe for unvaccinated at baseline and over the 14 days (P < 0.001). Individual symptoms were least severe in the vaccine-boosted group including: cough, chills, fever, nausea, fatigue, myalgia, headache, and diarrhea, as well as smell and taste abnormalities. Results were consistent over delta and omicron variant time periods. SARS-CoV-2 vaccine-boosted participants had the least severe symptoms during COVID-19 which abated the quickest over time. |
X Demographics
The data shown below were collected from the profiles of 906 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 174 | 19% |
| United States | 89 | 10% |
| Canada | 12 | 1% |
| United Kingdom | 7 | <1% |
| Belgium | 6 | <1% |
| France | 6 | <1% |
| Australia | 4 | <1% |
| India | 4 | <1% |
| Germany | 3 | <1% |
| Other | 34 | 4% |
| Unknown | 567 | 63% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 828 | 91% |
| Scientists | 41 | 5% |
| Practitioners (doctors, other healthcare professionals) | 29 | 3% |
| Science communicators (journalists, bloggers, editors) | 7 | <1% |
| Unknown | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 3 | 13% |
| Student > Bachelor | 2 | 9% |
| Student > Postgraduate | 2 | 9% |
| Student > Ph. D. Student | 2 | 9% |
| Unspecified | 1 | 4% |
| Other | 2 | 9% |
| Unknown | 11 | 48% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 17% |
| Nursing and Health Professions | 2 | 9% |
| Unspecified | 1 | 4% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Psychology | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 13 | 57% |
Attention Score in Context
This research output has an Altmetric Attention Score of 633. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 December 2023.
All research outputs
#35,585
of 25,791,949 outputs
Outputs from Clinical Infectious Diseases
#111
of 16,972 outputs
Outputs of similar age
#1,128
of 436,324 outputs
Outputs of similar age from Clinical Infectious Diseases
#5
of 215 outputs
Altmetric has tracked 25,791,949 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,972 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 31.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 436,324 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 215 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.